Brzozowski Zdzisław, Sławiński Jarosław, Saczewski Franciszek, Sanchez Tino, Neamati Nouri
Department of Chemical Technology of Drugs, Medical University of Gdańsk, Al. Gen. Hallera 107, 80-416 Gdańsk, Poland.
Eur J Med Chem. 2008 Jun;43(6):1188-98. doi: 10.1016/j.ejmech.2007.08.013. Epub 2007 Sep 11.
Several 4-chloro-N-(4-oxopyrimidin-2-yl)-2-mercaptobenzenesulfonamide derivatives 13-28 and 35-44 have been synthesized and tested as potential HIV-1 integrase (IN) inhibitors. Compounds 15-17, 19, 21-28, 36 and 41 inhibited IN with IC(50) values in the range of 3.3-63.0 microM. The compounds 13, 15, 16, 21-24 and 26-28 were further tested at the US National Cancer Institute for their in vitro activity against a panel of 53-57 human tumor cell lines. The compounds 26-28 were inactive, whereas the other compounds exhibited high or reasonable activity (GI(50)<0.01-20.0 microM) against one or more human tumor cell lines.
已合成了几种4-氯-N-(4-氧代嘧啶-2-基)-2-巯基苯磺酰胺衍生物13 - 28和35 - 44,并作为潜在的HIV-1整合酶(IN)抑制剂进行了测试。化合物15 - 17、19、21 - 28、36和41对IN具有抑制作用,IC(50)值在3.3 - 63.0微摩尔范围内。化合物13、15、16、21 - 24和26 - 28在美国国立癌症研究所进一步测试了它们对一组53 - 57种人类肿瘤细胞系的体外活性。化合物26 - 28无活性,而其他化合物对一种或多种人类肿瘤细胞系表现出高活性或合理活性(GI(50)<0.01 - 20.0微摩尔)。